TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Simponi, and UCB’s Cimzia) are approved to treat nonradiographic axial spondyloarthritis (nr-AxSpA) in Europe and are…
Clarivate Epidemiology’s coverage of primary immune thrombocytopenic purpura (ITP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…
Non-small-cell lung cancer (NSCLC)—the primary cause of cancer-related mortality in China—has a very dynamic pipeline that includes numerous targeted and biomarker-driven therapies. Notably,…
The negative symptoms of schizophrenia, which often coexist with the positive symptoms, include diminished emotional expression (affective flattening), diminished initiation of goal-directed…
Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…
Relapsed / refractory diffuse large B-cell lymphoma (R/R DLBCL) is an aggressive disease with significant unmet need. The treatment landscape has evolved since the approval of various novel…
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates,omega-3 fatty acid compounds, and PCSK9…
The age-related macular degeneration (AMD) market in the United States is unique given that market penetration of approved branded therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea,…
Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…